ES2161698T3 - Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia. - Google Patents

Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia.

Info

Publication number
ES2161698T3
ES2161698T3 ES93100339T ES93100339T ES2161698T3 ES 2161698 T3 ES2161698 T3 ES 2161698T3 ES 93100339 T ES93100339 T ES 93100339T ES 93100339 T ES93100339 T ES 93100339T ES 2161698 T3 ES2161698 T3 ES 2161698T3
Authority
ES
Spain
Prior art keywords
diagnosis
therapy
production
antibodies against
specific antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93100339T
Other languages
English (en)
Inventor
Klaus Bosslet
Beate Kehrel
Gerhard Seemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2161698T3 publication Critical patent/ES2161698T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS MONOCRONALES Y SUS PARTES, QUE LIGAN DE FORMA PREFERENCIAL EN PLAQUETAS HUMANAS ACTIVAS, LA SECUENCIA DE NUCLEOTIDOS Y AMINOACIDOS DE CADENAS LIGERAS O PESADAS EL MAK BW 2128 Y UN ANTIGENO ASOCIADO CON LA TROMBOSPONDINA.
ES93100339T 1992-02-07 1993-01-12 Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia. Expired - Lifetime ES2161698T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4203545A DE4203545A1 (de) 1992-02-07 1992-02-07 Spezifische antikoerper gegen aktivierte plaettchen, ihre herstellung und ihre verwendung in diagnose und therapie

Publications (1)

Publication Number Publication Date
ES2161698T3 true ES2161698T3 (es) 2001-12-16

Family

ID=6451181

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93100339T Expired - Lifetime ES2161698T3 (es) 1992-02-07 1993-01-12 Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia.

Country Status (9)

Country Link
US (1) US5686583A (es)
EP (1) EP0554670B1 (es)
JP (1) JP3821858B2 (es)
AT (1) ATE205255T1 (es)
AU (1) AU669870B2 (es)
CA (1) CA2088889C (es)
DE (2) DE4203545A1 (es)
ES (1) ES2161698T3 (es)
NO (1) NO930406L (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610960A (en) * 1983-12-21 1986-09-09 Wisconsin Alumni Research Foundation Monoclonal antibody to thrombospondin and method for assaying for and isolating thrombospondin
EP0387380A1 (en) * 1989-03-17 1990-09-19 BEHRINGWERKE Aktiengesellschaft Mutants of urinary plasminogen activator, their production and use
AU6964891A (en) * 1989-11-03 1991-05-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Novel monoclonal antibody against human platelets
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
WO1992017499A1 (en) * 1991-04-08 1992-10-15 Cornell Research Foundation, Inc. A unique hexapeptide derived from thrombospondin and its uses
CA2063055A1 (en) * 1991-05-22 1992-11-23 Jacob Eyal Peptides having thrombospondin-like activity and their therapeutic use

Also Published As

Publication number Publication date
DE4203545A1 (de) 1993-08-12
JP3821858B2 (ja) 2006-09-13
CA2088889C (en) 2009-08-25
EP0554670A2 (de) 1993-08-11
NO930406L (no) 1993-08-09
DE59310204D1 (de) 2001-10-11
ATE205255T1 (de) 2001-09-15
AU3283693A (en) 1993-08-12
CA2088889A1 (en) 1993-08-08
JPH06133768A (ja) 1994-05-17
NO930406D0 (no) 1993-02-05
EP0554670A3 (en) 1994-07-13
US5686583A (en) 1997-11-11
EP0554670B1 (de) 2001-09-05
AU669870B2 (en) 1996-06-27

Similar Documents

Publication Publication Date Title
ES2081857T3 (es) Nuevos inhibidores de alpha-glucosidasa.
ES2085075T3 (es) Imidas y sus sales, asi como su uso como agentes tensioactivos.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
TR199501021A2 (tr) Vücut agirligi modülatörüne tekabül eden nükleik asitler ve proteinler ve bunlarin diagnostik ve terapötik kullanimlari.
SV1996000033A (es) Isotiazolonas
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
NO963239L (no) Klorpyrimid-mellomprodukter
PT641343E (pt) Derivados de 4-mercaptoacetilamino-¬2|benzazapinona (3) e a sua utilizacao como inibidores de encefalinase
BR9806764A (pt) Moléculas mutantes ctla4 solúveis e usos das mesmas.
BR9408292A (pt) Antigens de esperma correspondente a um epitojo auto- antigênico de uma proteina de ligação a zona de esperma
ES2035668T3 (es) Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
HN1998000088A (es) Tratamiento de resistencia a la insulina
HN1998000169A (es) Uso de aminometilcromano sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal.
ES2153113T3 (es) Compuestos de benzotiofeno.
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
MX9302614A (es) Receptor de glutamato metabotropico humano y compuestos de dna relacionados.
ES2136583T1 (es) Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ES2161698T3 (es) Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia.
ES2192610T3 (es) Aminouracilos substituidos.
PT734380E (pt) 4-benzoilisoxazois e sua utilizacao como herbicidas
DK0639971T3 (da) Terapeutiske kombinationer
ES2117475T5 (es) Utilizacion de acidos monocarboxilicos para el tratamiento de las materias queratinicas.
BR0113172A (pt) Corpos enformados planos flexìveis, revestidos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 554670

Country of ref document: ES